Phase II Study of 5'-deoxy-5-fluorouridine (doxifluridine) in Advanced Malignant Melanoma

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1986 Jan 1

PMID 2933177

Citations 5

Authors

P Alberto

M Rozencweig

M Clavel

P Siegenthaler

F Cavalli

S Gundersen

U Bruntsch

J Renard

H Pinedo

Affiliations

Soon will be listed here.

Abstract

Forty-two patients with malignant melanoma were treated with doxifluridine, 4000 mg/m2 daily X 5, repeated every 3 weeks. The daily dose was reduced to 3000 mg/m2 in patients who had experienced severe myelosuppression with prior chemotherapy. A total of 35 patients were evaluable for response, and 25 of these received two or more courses. Two responses were observed. Toxicity mainly took the form of nausea, vomiting, stomatitis, dizziness, ataxia, and fatigue. Mild leukopenia was frequent (43%). Nadir counts less than 1.5 X 10(9)/l leukocytes or 50 X 10(9)/l platelets were seen in 7% and 2% of the courses respectively. Doxifluridine has no useful activity against malignant melanoma.

Citing Articles

Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats.

Au J, Wientjes M, Bramer S Cancer Chemother Pharmacol. 1988; 22(1):5-10.

PMID: 2969304 DOI: 10.1007/BF00254172.

Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry.

Malet-Martino M, Servin P, Bernadou J, Armand J, Martino R Invest New Drugs. 1987; 5(3):273-9.

PMID: 2959633 DOI: 10.1007/BF00175298.

Absorption of 5'-deoxy-5-fluorouridine from colon.

Au J, Gunnarsson L Pharm Res. 1989; 6(4):323-7.

PMID: 2526329 DOI: 10.1023/a:1015902625456.

Biologic activity of 5'-deoxy-5-fluorouridine by rectal administration.

Bramer S, Gunnarsson L, Au J Pharm Res. 1989; 6(4):318-22.

PMID: 2526328 DOI: 10.1023/a:1015950508618.

Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine.

Ninomiya Y, Miwa M, Eda H, Sahara H, Fujimoto K, Ishida M Jpn J Cancer Res. 1990; 81(2):188-95.

PMID: 2139643 PMC: 5963899. DOI: 10.1111/j.1349-7006.1990.tb02547.x.

References

Armstrong R, Diasio R . Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index. Cancer Res. 1981; 41(12 Pt 1):4891-4. View

Leyva A, Kraal I, Lankelma J, Delemarre J, Pinedo H . High uridine phosphorylase activity in human melanoma tumor. Anticancer Res. 1983; 3(4):227-31. View

Abele R, Alberto P, Seematter R, Germano G, HEINTZ R, BOLLAG W . Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative. Cancer Treat Rep. 1982; 66(6):1307-13. View

Armstrong R, Diasio R . Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res. 1980; 40(9):3333-8. View

Abele R, Alberto P, Kaplan S, Siegenthaler P, Hofmann V, Ryssel H . Phase II study of doxifluridine in advanced colorectal adenocarcinoma. J Clin Oncol. 1983; 1(12):750-4. DOI: 10.1200/JCO.1983.1.12.750. View